Emerson Selected to Automate $2B Louisiana Green Fuels Project
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy EMR?
Emerson has been chosen to automate Strategic Biofuels' $2B landmark Louisiana Green Fuels power facility in Caldwell Parish. The project consists of a wood-fired power plant fully integrated with commercial-scale carbon capture and sequestration, delivering carbon-neutral electricity to Louisiana's grid. At full operation, LGF will convert 1.3 million tons of forestry residuals each year-material that would otherwise be left to decompose or be burned-into renewable baseload power, while capturing and permanently storing 1.1 million metric tons of CO2 annually in secure geologic formations nearly a mile underground. The project will generate 100 MW of clean, dispatchable electricity, positioning Louisiana as a leader in carbon-neutral energy production. Emerson will deploy its DeltaV Automation Platform, along with a full suite of advanced automation, measurement and reliability technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMR
Wall Street analysts forecast EMR stock price to rise
14 Analyst Rating
7 Buy
6 Hold
1 Sell
Moderate Buy
Current: 142.660
Low
125.00
Averages
150.46
High
170.00
Current: 142.660
Low
125.00
Averages
150.46
High
170.00
About EMR
Emerson Electric Co. is a global technology and software company that provides solutions for customers in a wide range of end markets around the world. The Company operates through seven segments under two business groups, such as Intelligent Devices and Software and Control. Its Intelligent Devices business includes Final Control, Measurement & Analytical, Discrete Automation, and Safety & Productivity. Software and Control business includes Control Systems & Software, Test & Measurement, and AspenTech. Its Final Control segment is a global provider of control valves, isolation valves, shutoff valves, pressure relief valves, pressure safety valves, actuators, and regulators for process and hybrid industries. Its Measurement & Analytical segment is a supplier of intelligent instrumentation measuring the physical properties of liquids or gases. AspenTech segment provides asset optimization software that enables industrial manufacturers to design, operate and maintain their operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharmaceutical Industry Accelerates AI Compliance Transformation
- AI-Driven Compliance Monitoring: Pharmaceutical manufacturers are shifting towards AI-driven real-time monitoring systems that dynamically assess compliance throughout the production process, thereby reducing human error and enhancing data integrity to meet increasingly stringent regulatory demands.
- FDA Support for New Technologies: The U.S. FDA encourages the adoption of advanced manufacturing technologies and continuous production models, which is driving the pharmaceutical industry towards intelligent, automated compliance infrastructures, reducing the risk of manufacturing failures and supply disruptions.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant evolution in pharmaceutical development and manufacturing, integrating AI, robotics, and advanced analytics to enhance productivity and product quality while promoting data-driven decision-making.
- Significant Market Potential: The global pharmaceutical manufacturing market is expected to reach $1 trillion, with investments increasingly directed towards automation and digital infrastructure, indicating a strategic shift in companies' focus towards compliance and efficiency.
See More
Pharmaceutical Industry Shifts to AI-Driven Compliance
- AI-Driven Compliance Transformation: Pharmaceutical manufacturers are increasingly integrating artificial intelligence into production workflows for real-time compliance monitoring, replacing traditional manual checks and retrospective audits, thereby enhancing production efficiency and reducing human error risks.
- FDA Support for New Technologies: The U.S. Food and Drug Administration (FDA) is promoting the adoption of advanced manufacturing technologies, encouraging companies to implement real-time data monitoring to ensure product quality and minimize manufacturing failure risks, which introduces new compliance standards for the industry.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant transformation in the pharmaceutical industry, integrating artificial intelligence, robotics, and data analytics to enhance production efficiency and product quality while driving data-driven decision-making processes.
- Significant Market Potential: The global pharmaceutical manufacturing market is projected to reach $1 trillion, with increasing investments in automation and digital infrastructure, indicating the industry's focus on intelligent manufacturing and compliance will drive sustainable growth.
See More
Emerson Supports First Biomass Carbon Capture Facility
- Project Scale and Investment: Strategic Biofuels is investing $2 billion in its Louisiana Green Fuels facility, which will convert 1.3 million tons of forestry residuals into renewable power annually, demonstrating a strong commitment to sustainable energy.
- Carbon Capture Capacity: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year in secure geological formations nearly a mile underground, positioning Louisiana as a leader in carbon-neutral energy production.
- Automation Technology Application: Emerson will deploy its DeltaV™ Automation Platform along with a suite of advanced automation and measurement technologies to optimize the plant's integrated operations, ensuring timely project completion and enhanced operational efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer highlighted that the project will not only convert waste biomass into reliable power but also permanently remove carbon from the atmosphere through carbon capture technology, driving the future of clean energy.
See More
Emerson Automates Landmark Carbon Capture Biomass Facility
- Project Scale and Investment: Emerson has been selected to provide automation solutions for Strategic Biofuels' $2 billion biomass power facility in Louisiana, which will convert 1.3 million tons of forestry waste into renewable electricity annually, significantly enhancing local clean energy production.
- Carbon Capture Capability: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year using advanced carbon capture and sequestration technologies, positioning Louisiana as a leader in carbon-neutral energy and aligning with global emission reduction goals.
- Technology Application and Optimization: Emerson will deploy its DeltaV™ Automation Platform along with a full suite of advanced automation and measurement technologies to ensure efficient, safe, and continuous operation of the project, thereby reducing operational risks and enhancing overall efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer noted that this project not only serves as an innovative demonstration of clean energy but also lays the groundwork for a replicable commercial pathway for the future, showcasing the company's leadership in energy transition infrastructure.
See More
JDIV ETF Shows Global Dividend Strategy Success
- Global Dividend Strategy: The JPMorgan Dividend Leaders ETF (JDIV) allocates approximately 51% of its assets to U.S. stocks while diversifying globally, demonstrating a strategy aimed at seeking stable returns amid market turbulence.
- Outperformance Against Market: As of Tuesday, JDIV's year-to-date total return stands at -1.43%, outperforming the S&P 500's -4.33%, indicating its resilience during market volatility.
- Dividend Growth Expectations: JDIV is projected to achieve an 8% dividend growth over the next five years, surpassing the global stock expectation of 7%, reflecting its investment strategy in high-quality companies.
- Avoiding AI Risks: JDIV steers clear of excessive bets on artificial intelligence, focusing instead on stable income growth, ensuring investor confidence amid market uncertainties.
See More
Wall Street's Latest Ratings Overview
- Visa and Mastercard Ratings: Loop initiates coverage on Visa and Mastercard with a buy rating, anticipating significant net revenue growth driven by market share gains and upside from foreign exchange volatility, enhancing their competitive edge in the payment processing sector.
- Arista and Cisco Buy Ratings: Truist initiates buy ratings for Arista Networks and Cisco, citing their high-quality business scale and thematic attractiveness, particularly in the data center growth space, which presents underappreciated opportunities.
- 10X Genomics Upgrade: William Blair upgrades 10X Genomics from market perform to outperform, highlighting its pivotal role in AI drug discovery and improved profitability, which is expected to drive future growth following five consecutive topline beats.
- MiniMed Platform Outlook: Morgan Stanley initiates MiniMed at overweight with a $19 price target, projecting that its differentiated diabetes management platform will drive growth and margin expansion, particularly given the significant underpenetration in the U.S. market.
See More
Pharmaceutical Industry Accelerates AI Compliance Transformation
- AI-Driven Compliance Monitoring: Pharmaceutical manufacturers are shifting towards AI-driven real-time monitoring systems that dynamically assess compliance throughout the production process, thereby reducing human error and enhancing data integrity to meet increasingly stringent regulatory demands.
- FDA Support for New Technologies: The U.S. FDA encourages the adoption of advanced manufacturing technologies and continuous production models, which is driving the pharmaceutical industry towards intelligent, automated compliance infrastructures, reducing the risk of manufacturing failures and supply disruptions.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant evolution in pharmaceutical development and manufacturing, integrating AI, robotics, and advanced analytics to enhance productivity and product quality while promoting data-driven decision-making.
- Significant Market Potential: The global pharmaceutical manufacturing market is expected to reach $1 trillion, with investments increasingly directed towards automation and digital infrastructure, indicating a strategic shift in companies' focus towards compliance and efficiency.
See More
Pharmaceutical Industry Shifts to AI-Driven Compliance
- AI-Driven Compliance Transformation: Pharmaceutical manufacturers are increasingly integrating artificial intelligence into production workflows for real-time compliance monitoring, replacing traditional manual checks and retrospective audits, thereby enhancing production efficiency and reducing human error risks.
- FDA Support for New Technologies: The U.S. Food and Drug Administration (FDA) is promoting the adoption of advanced manufacturing technologies, encouraging companies to implement real-time data monitoring to ensure product quality and minimize manufacturing failure risks, which introduces new compliance standards for the industry.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant transformation in the pharmaceutical industry, integrating artificial intelligence, robotics, and data analytics to enhance production efficiency and product quality while driving data-driven decision-making processes.
- Significant Market Potential: The global pharmaceutical manufacturing market is projected to reach $1 trillion, with increasing investments in automation and digital infrastructure, indicating the industry's focus on intelligent manufacturing and compliance will drive sustainable growth.
See More
Emerson Supports First Biomass Carbon Capture Facility
- Project Scale and Investment: Strategic Biofuels is investing $2 billion in its Louisiana Green Fuels facility, which will convert 1.3 million tons of forestry residuals into renewable power annually, demonstrating a strong commitment to sustainable energy.
- Carbon Capture Capacity: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year in secure geological formations nearly a mile underground, positioning Louisiana as a leader in carbon-neutral energy production.
- Automation Technology Application: Emerson will deploy its DeltaV™ Automation Platform along with a suite of advanced automation and measurement technologies to optimize the plant's integrated operations, ensuring timely project completion and enhanced operational efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer highlighted that the project will not only convert waste biomass into reliable power but also permanently remove carbon from the atmosphere through carbon capture technology, driving the future of clean energy.
See More
Emerson Automates Landmark Carbon Capture Biomass Facility
- Project Scale and Investment: Emerson has been selected to provide automation solutions for Strategic Biofuels' $2 billion biomass power facility in Louisiana, which will convert 1.3 million tons of forestry waste into renewable electricity annually, significantly enhancing local clean energy production.
- Carbon Capture Capability: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year using advanced carbon capture and sequestration technologies, positioning Louisiana as a leader in carbon-neutral energy and aligning with global emission reduction goals.
- Technology Application and Optimization: Emerson will deploy its DeltaV™ Automation Platform along with a full suite of advanced automation and measurement technologies to ensure efficient, safe, and continuous operation of the project, thereby reducing operational risks and enhancing overall efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer noted that this project not only serves as an innovative demonstration of clean energy but also lays the groundwork for a replicable commercial pathway for the future, showcasing the company's leadership in energy transition infrastructure.
See More
JDIV ETF Shows Global Dividend Strategy Success
- Global Dividend Strategy: The JPMorgan Dividend Leaders ETF (JDIV) allocates approximately 51% of its assets to U.S. stocks while diversifying globally, demonstrating a strategy aimed at seeking stable returns amid market turbulence.
- Outperformance Against Market: As of Tuesday, JDIV's year-to-date total return stands at -1.43%, outperforming the S&P 500's -4.33%, indicating its resilience during market volatility.
- Dividend Growth Expectations: JDIV is projected to achieve an 8% dividend growth over the next five years, surpassing the global stock expectation of 7%, reflecting its investment strategy in high-quality companies.
- Avoiding AI Risks: JDIV steers clear of excessive bets on artificial intelligence, focusing instead on stable income growth, ensuring investor confidence amid market uncertainties.
See More
Wall Street's Latest Ratings Overview
- Visa and Mastercard Ratings: Loop initiates coverage on Visa and Mastercard with a buy rating, anticipating significant net revenue growth driven by market share gains and upside from foreign exchange volatility, enhancing their competitive edge in the payment processing sector.
- Arista and Cisco Buy Ratings: Truist initiates buy ratings for Arista Networks and Cisco, citing their high-quality business scale and thematic attractiveness, particularly in the data center growth space, which presents underappreciated opportunities.
- 10X Genomics Upgrade: William Blair upgrades 10X Genomics from market perform to outperform, highlighting its pivotal role in AI drug discovery and improved profitability, which is expected to drive future growth following five consecutive topline beats.
- MiniMed Platform Outlook: Morgan Stanley initiates MiniMed at overweight with a $19 price target, projecting that its differentiated diabetes management platform will drive growth and margin expansion, particularly given the significant underpenetration in the U.S. market.
See More
